Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOEL R SAPER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Pain Medicine

NPI
1891888095
CMS profile
358295
Location
ANN ARBOR, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$867.79

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $742.80 3
Food and Beverage $124.99 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Promius Pharma LLC $720.40 2
Lundbeck LLC $147.39 2

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOEL R SAPER

NPI 1891888095 · CMS profile ID 358295

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Pain Medicine

ANN ARBOR, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1891888095?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOEL R SAPER, NPI 1891888095, CMS profile ID 358295. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1891888095?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JOEL R SAPER, NPI 1891888095, CMS profile ID 358295. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1891888095?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JOEL R SAPER, NPI 1891888095, CMS profile ID 358295, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1891888095?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $867.79 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lundbeck LLC $22.4011/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684345371 CMS
Lundbeck LLC $124.9911/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684345377 CMS
Promius Pharma LLC $574.4002/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701097285 CMS
Promius Pharma LLC $146.0001/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701097283 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $867.79 4
PY2024 $34.38 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $741,643.58 208
PY2024 Principal investigator $778,871.45 258
PY2023 Recipient $188,670.14 42
PY2023 Principal investigator $817,852.03 284
PY2022 Recipient $694.00 1
PY2022 Principal investigator $856,999.67 290
PY2021 Principal investigator $1,105,932.40 208
PY2020 Principal investigator $729,753.82 96
PY2019 Recipient $20,043.40 4
PY2019 Principal investigator $688,115.98 92

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

96 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $22,335.00 12/31/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670122779
Principal investigator 1 Amgen Inc. $9,991.64 12/24/2019 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Ph3 Pediatric CM Study No dispute reported 06/30/2026 675778399
Principal investigator 1 Amgen Inc. $5,018.00 12/24/2019 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Phase P3 Pediatric Study (EM) No dispute reported 06/30/2026 675778579
Principal investigator 1 Amgen Inc. $11,329.00 12/21/2019 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Medication Overuse Headache Study (MOH) No dispute reported 06/30/2026 675778129
Principal investigator 1 Allergan Inc. $700.00 12/17/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670115907
Principal investigator 1 Allergan Inc. $11,552.00 12/13/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670110541
Principal investigator 1 Allergan Inc. $9,600.00 11/25/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGY
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670103503
Principal investigator 1 Amgen Inc. $6,150.00 11/23/2019 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Work Productivity Study No dispute reported 06/30/2026 675787967
Principal investigator 1 Allergan Inc. $8,168.10 11/13/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670096721
Principal investigator 1 Allergan Inc. $86.00 11/12/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670095897
Principal investigator 1 Allergan Inc. $327.00 11/12/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670096121
Principal investigator 1 Allergan Inc. $8,400.00 11/08/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGY
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670095235
Principal investigator 1 Amgen Inc. $5,512.45 11/08/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Work Productivity Study No dispute reported 06/30/2026 675787953
Principal investigator 1 Allergan Inc. $600.00 11/01/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670094089
Principal investigator 1 Allergan Inc. $12,169.50 10/15/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670085587
Principal investigator 1 Amgen Inc. $8,062.66 10/08/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Medication Overuse Headache Study (MOH) No dispute reported 06/30/2026 675787941
Principal investigator 1 Amgen Inc. $9,634.86 10/08/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Ph3 Pediatric CM Study No dispute reported 06/30/2026 675787945
Principal investigator 1 Amgen Inc. $650.00 09/30/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL INSTITUTE
Ph3 Pediatric CM Study No dispute reported 06/30/2026 675787937
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $11,236.97 09/30/2019 Non-covered Recipient Entity
Michigan Head Pain & Neurological Inst.
A Study to Explore the Long-Term Safety and Efficacy of TEV-48125 (Fremanezumab) for the Prevention of Cluster Headache (ENFORCE) No dispute reported 06/30/2026 685015889
Principal investigator 1 Allergan Inc. $11,270.80 09/18/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670076697
Principal investigator 1 Avanir Pharmaceuticals, Inc. $818.34 09/12/2019 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE, PC
17-AVP-825-301 No dispute reported 06/30/2026 656017357
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,410.30 09/09/2019 Non-covered Recipient Entity
Michigan Head-Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients With Inadequate Response to Prior Preventive Treatments No dispute reported 06/30/2026 685026307
Principal investigator 1 Allergan Inc. $86.00 09/05/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670073117
Principal investigator 1 Allergan Inc. $86.00 09/03/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670071793
Principal investigator 1 Amgen Inc. $5,174.40 09/01/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL I
Ph3 Pediatric CM Study No dispute reported 06/30/2026 675787919
Principal investigator 1 Amgen Inc. $5,500.00 08/23/2019 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Medication Overuse Headache Study (MOH) No dispute reported 06/30/2026 675787957
Principal investigator 1 Amgen Inc. $7,761.60 08/19/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL I
Medication Overuse Headache Study (MOH) No dispute reported 06/30/2026 675787917
Principal investigator 1 Allergan Inc. $22,723.05 08/14/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670065373
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $130.00 08/12/2019 Non-covered Recipient Entity
Michigan Head-Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients With Inadequate Response to Prior Preventive Treatments No dispute reported 06/30/2026 685026291
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 08/12/2019 Non-covered Recipient Entity
Michigan Head-Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients With Inadequate Response to Prior Preventive Treatments No dispute reported 06/30/2026 685026299
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $950.00 08/12/2019 Non-covered Recipient Entity
Michigan Head-Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients With Inadequate Response to Prior Preventive Treatments No dispute reported 06/30/2026 685026313
Principal investigator 1 Amgen Inc. $191.15 08/08/2019 Non-covered Recipient Entity
MICHIGAN HEAD NEURO INSTI
Medication Overuse Headache Study (MOH) No dispute reported 06/30/2026 675787915
Principal investigator 1 Avanir Pharmaceuticals, Inc. $3,286.00 08/01/2019 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE, PC
17-AVP-825-301 No dispute reported 06/30/2026 656017355
Principal investigator 1 Allergan Inc. $10,000.00 07/31/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGY
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670062099
Principal investigator 1 Allergan Inc. $10,000.00 07/31/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGY
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670062107
Principal investigator 1 Amgen Inc. $5,500.00 07/23/2019 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Ph3 Pediatric CM Study No dispute reported 06/30/2026 675787961
Principal investigator 1 Amgen Inc. $17,274.00 07/23/2019 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Phase P3 Pediatric Study (EM) No dispute reported 06/30/2026 675787965
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,250.00 07/18/2019 Non-covered Recipient Entity
Michigan Head Pain & Neurological Inst.
A Study to Explore the Long-Term Safety and Efficacy of TEV-48125 (Fremanezumab) for the Prevention of Cluster Headache (ENFORCE) No dispute reported 06/30/2026 685015821
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,250.00 07/18/2019 Non-covered Recipient Entity
Michigan Head Pain & Neurological Inst.
A Study to Explore the Long-Term Safety and Efficacy of TEV-48125 (Fremanezumab) for the Prevention of Cluster Headache (ENFORCE) No dispute reported 06/30/2026 685015827
Principal investigator 1 Allergan Inc. $15,432.75 07/15/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670057001
Principal investigator 1 Amgen Inc. $1,901.66 07/12/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL INSTITUTE
Work Productivity Study No dispute reported 06/30/2026 675787939
Principal investigator 1 Amgen Inc. $395.63 07/09/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL INSTITUTE
Medication Overuse Headache Study (MOH) No dispute reported 06/30/2026 675787935
Principal investigator 1 Eli Lilly and Company $33.61 06/17/2019 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
A PHASE 3B MULTICENTER, SINGLE-ARM, OPEN-LABEL SAFETY STUDY OF LY2951742 -GALCANEZUMAB- IN PATIENTS WITH EPISODIC OR CHRONIC CLUSTER HEADACHE No dispute reported 06/30/2026 654286783
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,401.43 06/11/2019 Non-covered Recipient Entity
Michigan Head Pain & Neurological Inst.
A Study to Explore the Long-Term Safety and Efficacy of TEV-48125 (Fremanezumab) for the Prevention of Cluster Headache (ENFORCE) No dispute reported 06/30/2026 685009135
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $650.00 06/03/2019 Non-covered Recipient Entity
Michigan Head-Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients With Inadequate Response to Prior Preventive Treatments No dispute reported 06/30/2026 685008893
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $92.00 06/03/2019 Non-covered Recipient Entity
Michigan Head-Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients With Inadequate Response to Prior Preventive Treatments No dispute reported 06/30/2026 685008897
Principal investigator 1 Allergan Inc. $490.00 05/29/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGY
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670049397
Principal investigator 1 Allergan Inc. $289.00 05/29/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGY
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670049403
Principal investigator 1 Allergan Inc. $289.00 05/28/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGY
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670049215
Principal investigator 1 Amgen Inc. $860.17 05/13/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL INSTITUTE
Phase 2 Episodic Migraine Prophylaxis EMP No dispute reported 06/30/2026 675787931
Principal investigator 1 Amgen Inc. $10,348.80 05/12/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL I
Phase P3 Pediatric Study (EM) No dispute reported 06/30/2026 675787923
Principal investigator 1 Amgen Inc. $333.29 05/08/2019 Non-covered Recipient Entity
MI HDACH AND NEURO INST
Phase 2 Episodic Migraine Prophylaxis EMP No dispute reported 06/30/2026 675787879
Principal investigator 1 Amgen Inc. $496.73 05/08/2019 Non-covered Recipient Entity
MI HEAD PAIN AND NEURO INST
Phase P3 Pediatric Study (EM) No dispute reported 06/30/2026 675787881
Principal investigator 1 Allergan Inc. $13,394.05 04/25/2019 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670040909
Principal investigator 1 Dr.Reddy's Laboratories,Inc. $1,336.79 04/25/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL INSTITUTE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy, Tolerability, and Safety Study of DFN-15 in Episodic Migraine With or Without Aura No dispute reported 06/30/2026 701426077
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $12,128.14 04/16/2019 Non-covered Recipient Entity
Michigan Head Pain & Neurological Inst.
A Study to Explore the Long-Term Safety and Efficacy of TEV-48125 (Fremanezumab) for the Prevention of Cluster Headache (ENFORCE) No dispute reported 06/30/2026 685009073
Principal investigator 1 Amgen Inc. $2,701.87 04/12/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL INSTITUTE
Ph3 Pediatric CM Study No dispute reported 06/30/2026 675787929
Principal investigator 1 Amgen Inc. $3,828.13 04/11/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL INSTITUTE
Phase P3 Pediatric Study (EM) No dispute reported 06/30/2026 675787933
Principal investigator 1 Avanir Pharmaceuticals, Inc. $9,057.50 04/11/2019 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE, PC
17-AVP-825-301 No dispute reported 06/30/2026 656017351
Principal investigator 1 Amgen Inc. $862.40 04/09/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL I
Phase 2 Episodic Migraine Prophylaxis EMP No dispute reported 06/30/2026 675787921
Principal investigator 1 Eli Lilly and Company $2,989.00 04/09/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 WITH A LONG-TERM OPEN-LABEL EXTENSION IN PATIENTS WITH CHRONIC CLUSTER HEADACHE No dispute reported 06/30/2026 654294047
Principal investigator 1 Amgen Inc. $240.43 04/08/2019 Non-covered Recipient Entity
MI HEAD PAIN AND NEURO INST.
Ph3 Pediatric CM Study No dispute reported 06/30/2026 675787883
Principal investigator 1 Amgen Inc. $0.50 04/08/2019 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITUTE
P2 Migraine Proof of Concept No dispute reported 06/30/2026 675787955
Principal investigator 1 Amgen Inc. $1,070.00 04/05/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL INSTITUTE
P2 Migraine Proof of Concept No dispute reported 06/30/2026 675787927
Principal investigator 1 Amgen Inc. $1,345.72 04/04/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN & NEUROLOGICAL INSTITUTE
Medication Overuse Headache Study (MOH) No dispute reported 06/30/2026 675787925
Principal investigator 1 Novartis Pharmaceuticals Corporation $24,167.20 04/01/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
A 12 MONTHS PROSPECTIVE, INTERVENTIONAL, MULTINATIONAL, OPEN-LABEL, ACTIVE-CONTROLLED STUDY COMPARING SUSTAINED BENEFIT OF TWO TREATMENT PARADIGMS (ERENUMAB 140 MG QM VS ORAL PROPHYLACTICS) No dispute reported 06/30/2026 640720641
Principal investigator 1 Allergan Inc. $16,130.05 03/26/2019 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670033551
Principal investigator 1 Eli Lilly and Company $356.25 03/26/2019 Covered Recipient Teaching Hospital
COMMUNITY HOSPITAL ANDERSON
A PHASE 3B MULTICENTER, SINGLE-ARM, OPEN-LABEL SAFETY STUDY OF LY2951742 -GALCANEZUMAB- IN PATIENTS WITH EPISODIC OR CHRONIC CLUSTER HEADACHE No dispute reported 06/30/2026 654285487
Principal investigator 1 Amgen Inc. $23,595.22 03/20/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Phase 2 Episodic Migraine Prophylaxis EMP No dispute reported 06/30/2026 675787947
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,554.76 03/08/2019 Non-covered Recipient Entity
Michigan Head Pain & Neurological Inst.
Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine No dispute reported 06/30/2026 685007359
Principal investigator 1 Eli Lilly and Company $2,073.80 03/07/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
AN OPEN LABEL, LONG TERM, SAFETY STUDY OF LASMIDITAN 100 MG AND 200 MG IN THE ACUTE TREATMENT OF MIGRAINE GLADIATOR No dispute reported 06/30/2026 654291123
Principal investigator 1 Amgen Inc. $6,178.97 03/01/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Phase P3 Pediatric Study (EM) No dispute reported 06/30/2026 675787951
Principal investigator 1 Allergan Inc. $8,915.75 02/28/2019 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670028093
Principal investigator 1 Amgen Inc. $3,832.00 02/26/2019 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
P2 Migraine Proof of Concept No dispute reported 06/30/2026 675787959
Recipient Eli Lilly and Company $128.40 02/25/2019 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE - THE CONQUER STUDY No dispute reported 06/30/2026 654282079
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,386.02 02/20/2019 Non-covered Recipient Entity
Michigan Head Pain & Neurological Inst.
A Study to Explore the Long-Term Safety and Efficacy of TEV-48125 (Fremanezumab) for the Prevention of Cluster Headache (ENFORCE) No dispute reported 06/30/2026 685007245
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $760.50 02/19/2019 Non-covered Recipient Entity
Michigan Head-Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients With Inadequate Response to Prior Preventive Treatments No dispute reported 06/30/2026 685007169
Principal investigator 1 Avanir Pharmaceuticals, Inc. $533.55 02/14/2019 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE, PC
17-AVP-825-301 No dispute reported 06/30/2026 656017349
Principal investigator 1 Avanir Pharmaceuticals, Inc. $631.66 02/07/2019 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE, PC
17-AVP-825-301 No dispute reported 06/30/2026 656017347
Principal investigator 1 Allergan Inc. $15,651.25 02/05/2019 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670021987
Principal investigator 1 Eli Lilly and Company $70,283.60 02/05/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
A PHASE 3B MULTICENTER, SINGLE-ARM, OPEN-LABEL SAFETY STUDY OF LY2951742 -GALCANEZUMAB- IN PATIENTS WITH EPISODIC OR CHRONIC CLUSTER HEADACHE No dispute reported 06/30/2026 654292223
Principal investigator 1 Eli Lilly and Company $65,716.76 02/05/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE - THE CONQUER STUDY No dispute reported 06/30/2026 654293095
Principal investigator 1 Eli Lilly and Company $500.00 01/31/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE - THE CONQUER STUDY No dispute reported 06/30/2026 654294049
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,081.00 01/28/2019 Non-covered Recipient Entity
Michigan Head Pain & Neurological Inst.
A Study to Explore the Long-Term Safety and Efficacy of TEV-48125 (Fremanezumab) for the Prevention of Cluster Headache (ENFORCE) No dispute reported 06/30/2026 685007207
Principal investigator 1 Amgen Inc. $53,262.77 01/26/2019 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL
Phase 2 Episodic Migraine Prophylaxis EMP No dispute reported 06/30/2026 675787963
Principal investigator 1 Avanir Pharmaceuticals, Inc. $9,867.50 01/17/2019 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE, PC
17-AVP-825-301 No dispute reported 06/30/2026 656017353
Principal investigator 1 Amgen Inc. $13,976.44 01/15/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
Phase 2 Episodic Migraine Prophylaxis EMP No dispute reported 06/30/2026 675787949
Principal investigator 1 Eli Lilly and Company $1,663.00 01/15/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
A PHASE 3B MULTICENTER, SINGLE-ARM, OPEN-LABEL SAFETY STUDY OF LY2951742 -GALCANEZUMAB- IN PATIENTS WITH EPISODIC OR CHRONIC CLUSTER HEADACHE No dispute reported 06/30/2026 654296003
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,521.00 01/14/2019 Non-covered Recipient Entity
Michigan Head-Pain & Neurological Institute
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients With Inadequate Response to Prior Preventive Treatments No dispute reported 06/30/2026 685007171
Recipient Eli Lilly and Company $7,589.00 01/08/2019 Covered Recipient Physician A PHASE 3B MULTICENTER, SINGLE-ARM, OPEN-LABEL SAFETY STUDY OF LY2951742 -GALCANEZUMAB- IN PATIENTS WITH EPISODIC OR CHRONIC CLUSTER HEADACHE No dispute reported 06/30/2026 654282853
Recipient Eli Lilly and Company $1,489.00 01/08/2019 Covered Recipient Physician A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 WITH A LONG-TERM OPEN-LABEL EXTENSION IN PATIENTS WITH CHRONIC CLUSTER HEADACHE No dispute reported 06/30/2026 654282981
Recipient Eli Lilly and Company $10,837.00 01/07/2019 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE - THE CONQUER STUDY No dispute reported 06/30/2026 654282979
Principal investigator 1 Allergan Inc. $12,498.20 01/03/2019 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 670014133
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $12,670.81 01/03/2019 Non-covered Recipient Entity
Michigan Head Pain & Neurological Inst.
A Study to Explore the Long-Term Safety and Efficacy of TEV-48125 (Fremanezumab) for the Prevention of Cluster Headache (ENFORCE) No dispute reported 06/30/2026 685007187
Principal investigator 1 Amgen Inc. $77.25 01/01/2019 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
P2 Migraine Proof of Concept No dispute reported 06/30/2026 675787943
Principal investigator 1 Amgen Inc. $77.25 01/01/2019 Non-covered Recipient Entity
RENOWN INSTITUTE FOR NEUROSCIENCES
Phase 2 Episodic Migraine Prophylaxis EMP No dispute reported 06/30/2026 675790875